Dominantly Inherited Alzheimer's Network (DIAN-TU)
Purpose
The purpose of the DIAN-TU Study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation. The DIAN-TU is planning to enroll into two types of trials: primary prevention trials and secondary prevention trials. Trial site staff will determine which study is best suited for each potential participant, based on their estimated years to (symptom) onset, or “EYO”. A person’s EYO takes into consideration the actual age of the participant and the age at which their parent or relative became symptomatic. Learn more at the DIAN-TU clinical trials site.
Eligibility
Participants eligible for the DIAN-TU Study are:
- Healthy adults age 18 or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for Alzheimer's.
- Cognitively normal to very mild or mild cognitive impairment. Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
- Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
- For more details, please see the DIAN-TU website.
UW ADRC Study Contact:
Coordinators:
Emmaline Seth | emmaseth@uw.edu |206-221-292
Chris Gallagher (he, him) | chrisgal@uw.edu | 206-685-1189
UW ADRC Site PI:
Suman Jayadev, MD